Latest:
Dr. Singh on the Potential Effects of Radiation Timing in Head and Neck Cancer
Anurag Singh, MD, discusses the potential effects of radiation timing in head and neck cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Alberto Farolfi, MD, PhD
Alberto Farolfi, MD, PhD, is a medical oncologist at Romagnolo Scientific Institute for the Study and Treatment of Tumors
Latest:
Dr Farolfi on a Real-World Study of Bevacizumab Plus SOC Therapy in Cervical Cancer
Alberto Farolfi, MD, PhD, discusses bevacizumab plus SOC in advanced cervical cancer and no contraindications for antiangiogenic agents.
Joan Carles Galceran, MD, PhD
Joan Carles Galceran, MD, PhD, is a medical oncologist in the Department of Oncology, Hospital Universitari Vall d'Hebron as Unit Coordinator genitourinary, central nervous system, sarcomas.
Latest:
Dr Carles Galceran on the Safety of Darolutamide with ADT and Docetaxel in Older Patients With mHSPC
Joan Carles Galceran, MD, PhD, discusses the safety of adding darolutamide to ADT and docetaxel in older patients with mHSPC.
Percy Lee, MD
Percy Lee, MD, is vice chair of Clinical Research in the Department of Radiation Oncology, medical director of Orange County & Coastal Region Radiation Oncology, and a professor in the Department of Radiation Oncology at City of Hope
Latest:
Dr Lee on the Importance of Multidisciplinary Collaboration in NSCLC Management
Percy Lee, MD, discusses the critical nature of multidisciplinary collaboration and notes lingering questions about the optimal use of SABR in NSCLC.
Thomas E. Hutson, DO, PharmD, PhD, FACP
Latest:
Final Analysis of Lenvatinib + Pembrolizumab vs Sunitinib in Patients With Advanced Renal Cell Carcinoma With or Without Bone Metastases in CLEAR
Thomas Hutson, DO, PharmD, PhD, FACP presents the latest findings from the CLEAR trial on lenvatinib + pembrolizumab vs sunitinib in patients with advanced renal cell carcinoma with or without bone metastases.
Katherine B. Peters, MD, PhD
Latest:
Monitoring DMG Treatment Response Using RANO 2.0 Criteria
Experts discuss the evolution of the Response Assessment in Neuro-Oncology (RANO) criteria culminating in RANO 2.0, which standardizes treatment response evaluation for gliomas by refining imaging benchmarks, simplifying measurement methods, and addressing challenges in distinguishing progression from treatment effects to enhance consistency in both clinical trials and routine practice.